Unicycive Therapeutics, Inc. (UNCY) stock
UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.53−0.04 (-1.12%)
Close on Nov 19, 2026Market cap $98.33MP/E –Yield –
Unicycive Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Unicycive Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$33.14M. For fiscal 2025 it was -$29.52M. The highest annual figure on record is -$2.02M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$29.52M | – |
| FY2024 | Dec 31, 2024 | -$32.12M | – |
| FY2023 | Dec 31, 2023 | -$20.77M | – |
| FY2022 | Dec 31, 2022 | -$18.05M | – |
| FY2021 | Dec 31, 2021 | -$8.98M | – |
| FY2020 | Dec 31, 2020 | -$2.02M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.14M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.34M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.96M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.99M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.26M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.25M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.40M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.94M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.75M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$779.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$731.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$717.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$626.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$336.00K | – |
See a number that looks wrong?